First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Keyphrases

• Adjusted Rates 50%
• Arterial Thromboembolic Events 33%
• Attenuation 16%
• BNT162b2 16%
• BNT162b2 COVID-19 Vaccine 100%
• BNT162b2 Vaccine 16%
• Case Series Analysis 50%
• ChAdOx1 100%
• Confidence Interval 16%
• Confounding by Indication 16%
• Estimated Incidence 16%
• First Dose 100%
• Hematological Adverse Events 16%
• Hemorrhagic Disease 100%
• Matched Case-control Study 16%
• Public Health Authorities 16%
• Rate Ratio 50%
• Residual Confounding 16%
• Scotland 100%
• Self-controlled Case Series 83%
• Thrombocytopenia 100%
• Thrombotic Thrombocytopenic Purpura 33%
• Vaccination 66%
• Vascular Adverse Events 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 40%
• Case-Control Study 20%
• COVID-19 Vaccine 100%
• Idiopathic Thrombocytopenic Purpura 40%
• Thrombocytopenia 20%
• Thromboembolism 100%
• Vaccination Policy 100%

Biochemistry, Genetics and Molecular Biology

• Case-Control Study 50%
• Idiopathic Thrombocytopenic Purpura 100%
• Thrombocytopenia 50%